Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.
์ข
๋ชฉ ์ฝ๋ AAPG
ํ์ฌ ์ด๋ฆAscentage Pharma Group International
์์ฅ์ผOct 28, 2019
CEOYang (Dajun)
์ง์ ์- -
์ ํDepository Receipt
ํ๊ณ ์ฐ๋ ์ข
๋ฃ- -
์ฃผ์68 Xinqing Road, Suzhou Industrial Park
๋์SUZHOU
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐChina
์ฐํธ ๋ฒํธ- -
์ ํ
์น์ฌ์ดํธhttps://www.ascentage.cn/
์ข
๋ชฉ ์ฝ๋ AAPG
์์ฅ์ผOct 28, 2019
CEOYang (Dajun)